These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 11168950

  • 1. Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.
    D'Amico G, Napodano P, Ferrario F, Rastaldi MP, Arrigo G.
    Kidney Int; 2001 Feb; 59(2):682-92. PubMed ID: 11168950
    [Abstract] [Full Text] [Related]

  • 2. Morphological features in IgA nephropathy.
    Ferrario F, Rastaldi MP, Napodano P.
    Ann Med Interne (Paris); 1999 Feb; 150(2):108-16. PubMed ID: 10392259
    [Abstract] [Full Text] [Related]

  • 3. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
    Pozzi C, Del Vecchio L, Locatelli F.
    G Ital Nefrol; 2002 Feb; 19(5):523-8. PubMed ID: 12439840
    [Abstract] [Full Text] [Related]

  • 4. Steroid and cyclophosphamide in IgA nephropathy.
    Roccatello D, Ferro M, Cesano G, Rossi D, Berutti S, Salomone M, Piccoli G, Sena LM.
    Nephrol Dial Transplant; 2000 Jun; 15(6):833-5. PubMed ID: 10831636
    [Abstract] [Full Text] [Related]

  • 5. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.
    Haas M, Jafri J, Bartosh SM, Karp SL, Adler SG, Meehan SM.
    Am J Kidney Dis; 2000 Oct; 36(4):709-18. PubMed ID: 11007672
    [Abstract] [Full Text] [Related]

  • 6. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F.
    J Nephrol; 2013 Oct; 26(1):86-93. PubMed ID: 22460183
    [Abstract] [Full Text] [Related]

  • 7. Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy.
    Kusano T, Takano H, Kang D, Nagahama K, Aoki M, Morita M, Kaneko T, Tsuruoka S, Shimizu A.
    Hum Pathol; 2016 Mar; 49():135-44. PubMed ID: 26826420
    [Abstract] [Full Text] [Related]

  • 8. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.
    Tumlin JA, Hennigar RA.
    Semin Nephrol; 2004 May; 24(3):256-68. PubMed ID: 15156530
    [Abstract] [Full Text] [Related]

  • 9. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
    Edström Halling S, Söderberg MP, Berg UB.
    Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 11. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.
    Roccatello D, Ferro M, Coppo R, Giraudo G, Quattrocchio G, Piccoli G.
    Nephrol Dial Transplant; 1995 Nov; 10(11):2054-9. PubMed ID: 8643167
    [Abstract] [Full Text] [Related]

  • 12. Vasculitic IgA nephropathy: prognosis and outcome.
    Pankhurst T, Lepenies J, Nightingale P, Howie AJ, Adu D, Harper L.
    Nephron Clin Pract; 2009 Nov; 112(1):c16-24. PubMed ID: 19342865
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of IgA nephropathy with chronic renal failure].
    Pozzi C.
    G Ital Nefrol; 2008 Nov; 25 Suppl 44():83-7. PubMed ID: 19048591
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
    Rasche FM, Klotz CH, Czock D, Karges W, Muche R, Jehle PM, Mertz A, Keller F.
    Nephron Clin Pract; 2003 Nov; 93(4):c131-6. PubMed ID: 12759581
    [Abstract] [Full Text] [Related]

  • 15. Behcet's disease and IgA nephropathy: report of this association in a patient from Brazil and literature review.
    Fernandes PF, Júnior GB, Barros FA, Sousa DC, Franco LM, Patrocínio RM.
    Invest Clin; 2006 Dec; 47(4):405-11. PubMed ID: 17176908
    [Abstract] [Full Text] [Related]

  • 16. Factors predicting progression of IgA nephropathies.
    Coppo R, D'Amico G.
    J Nephrol; 2005 Dec; 18(5):503-12. PubMed ID: 16299675
    [Abstract] [Full Text] [Related]

  • 17. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F, Ackermann D, Hilgers RD, Floege J.
    J Nephrol; 2008 Dec; 21(3):284-9. PubMed ID: 18587715
    [Abstract] [Full Text] [Related]

  • 18. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH, Lee JE, Park JH, Lim S, Jang HR, Kwon GY, Huh W, Jung SH, Kim YG, Oh HY, Kim DJ.
    Ann Med; 2016 Dec; 48(3):171-81. PubMed ID: 27031662
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T, Najafi I, Salimi BH, Broomand B.
    Ren Fail; 2011 Dec; 33(6):572-7. PubMed ID: 21663387
    [Abstract] [Full Text] [Related]

  • 20. Treatment of progressive IgA nephropathy: an update.
    Wang W, Chen N.
    Contrib Nephrol; 2013 Dec; 181():75-83. PubMed ID: 23689569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.